AZN logo

AstraZeneca PLC

AZN

AZN: A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

more

Show AZN Financials

Chart and Financial Data provided by TradingView

$AZN is featured in our Congress Long-Short strategy.

See All Strategies
All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of AZN by members of U.S. Congress

Politician Type Traded
Daniel Goldman House / D Sale $100,001 - $250,000 Jul. 10, 2023
Alan S. Lowenthal House / D Sale $1,001 - $15,000 Dec. 01, 2021
Dean Phillips House / D Exchange $1,001 - $15,000 Jul. 21, 2021
Sara Jacobs House / D Sale $15,001 - $50,000 Apr. 09, 2021
Alan S. Lowenthal House / D Purchase $1,001 - $15,000 Feb. 22, 2021
Alan S. Lowenthal House / D Purchase $15,001 - $50,000 Feb. 22, 2021
Alan S. Lowenthal House / D Purchase $962.54 Feb. 22, 2021
Greg Gianforte House / R Purchase $1,001 - $15,000 Dec. 01, 2020
Thomas Suozzi House / D Sale $15,001 - $50,000 Feb. 24, 2020
John Rutherford House / R Sale $1,001 - $15,000 Jan. 15, 2020
Thomas Suozzi House / D Purchase $15,001 - $50,000 Jan. 07, 2020
Mikie Sherrill House / D Sale $1,001 - $15,000 May. 28, 2019
Mikie Sherrill House / D Sale $1,001 - $15,000 May. 28, 2019
Mikie Sherrill House / D Sale $1,001 - $15,000 May. 28, 2019
Capito, Shelley Moore Senate / R Sale (Full) $1,001 - $15,000 Mar. 11, 2019
Nicholas Van Taylor House / R Sale $1,001 - $15,000 Jan. 14, 2019
Nicholas Van Taylor House / R Sale $1,001 - $15,000 Jan. 07, 2019
Earl Blumenauer House / D Purchase $1,001 - $15,000 Mar. 07, 2018
Capito, Shelley Moore Senate / R Purchase $1,001 - $15,000 Sep. 08, 2017
John Rutherford House / R Purchase $1,001 - $15,000 Jul. 11, 2017
Dwight Evans House / D Purchase $1,001 - $15,000 Dec. 30, 2016
Thomas Macarthur House / R Sale $15,001 - $50,000 Dec. 02, 2016
Thomas Macarthur House / R Purchase $50,001 - $100,000 Feb. 22, 2016
Mr. K. Michael Conaway House / R Sale $1,001 - $15,000 May. 07, 2014
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by AZN's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard
Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Protein kinase b inhibitors Sep. 19, 2023
  • Patent Title: Mpo inhibitors for use in medicine Aug. 29, 2023
  • Patent Title: Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases Aug. 22, 2023
  • Patent Title: Therapeutic dendrimers Aug. 08, 2023
  • Patent Title: Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors Jul. 04, 2023
  • Patent Title: Biomarkers and methods of treating cancer Jun. 27, 2023
  • Patent Title: Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors Jun. 20, 2023
  • Patent Title: Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors Jun. 13, 2023
  • Patent Title: Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors Jun. 13, 2023
  • Patent Title: Compounds and their use Jun. 06, 2023
  • Patent Title: Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors Jun. 06, 2023
  • Patent Title: Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors May. 23, 2023
  • Patent Title: Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors May. 23, 2023
  • Patent Title: Certain (2s)-n-[(1 s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors May. 23, 2023
  • Patent Title: Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors May. 23, 2023
  • Patent Title: Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer Mar. 28, 2023
  • Patent Title: Pcsk9 inhibitors and methods of use thereof Mar. 14, 2023
  • Patent Title: 2-(2,4,5-substituted-anilino)pyrimidine compounds Dec. 13, 2022
  • Patent Title: Mcl-1 inhibitors and methods of use thereof Oct. 18, 2022
  • Patent Title: Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof Oct. 04, 2022
  • Patent Title: Compounds Sep. 27, 2022
  • Patent Title: Halo-substituted piperidines as orexin receptor modulators Sep. 06, 2022
  • Patent Title: Arginase inhibitors and methods of use thereof Aug. 23, 2022
  • Patent Title: Tetracyclic heteroaryl compounds Aug. 09, 2022
  • Patent Title: [1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases Aug. 09, 2022
  • Patent Title: Medicament dispensing system and dispensing method Jul. 12, 2022
  • Patent Title: Pyridine and pyrimidine derivatives Jun. 07, 2022
  • Patent Title: Chemical compounds May. 10, 2022
  • Patent Title: Composition for inhalation Apr. 26, 2022
  • Patent Title: Gene modification assays Feb. 22, 2022
  • Patent Title: Pcsk9 inhibitors and methods of use thereof Feb. 15, 2022
  • Patent Title: Protein kinase b inhibitors Feb. 01, 2022
  • Patent Title: Process for the preparation of osimertinib (azd9291) or a salt thereof, and “azd9291 aniline” or a salt thereof Nov. 23, 2021
  • Patent Title: Salts of ijak inhibitors and methods of using the same Oct. 19, 2021
  • Patent Title: Synthesis of mcl-1 inhibitor Oct. 19, 2021
  • Patent Title: Amino-triazolopyridine compounds and their use in treating cancer Oct. 05, 2021
  • Patent Title: Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors Sep. 14, 2021
  • Patent Title: Phenoxyquinazoline compounds and their use in treating cancer Jul. 06, 2021
  • Patent Title: Selective estrogen receptor down-regulators Jun. 29, 2021
  • Patent Title: 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators Jun. 15, 2021
  • Patent Title: 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4h-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase May. 11, 2021
  • Patent Title: Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors May. 11, 2021
  • Patent Title: Inhaler counter May. 04, 2021
  • Patent Title: Compounds Apr. 27, 2021
  • Patent Title: Methods of treating heart failure with reduced ejection fraction Apr. 13, 2021
  • Patent Title: Jak1 selective inhibitors Mar. 30, 2021
  • Patent Title: (s)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino) thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one as a phosphatidylinositol 3-kinase inhibitor Mar. 30, 2021
  • Patent Title: Chemical compounds Mar. 30, 2021
  • Patent Title: Computer system and method for generating trigger alerts to maximize interactions with healthcare providers Mar. 23, 2021
  • Patent Title: Chemical compounds Mar. 23, 2021
Government Contracts

Federal grants, loans, and purchases

WallStreetBets

Number of mentions of AZN in WallStreetBets Daily Discussion

AZN News

Recent insights relating to AZN

CNBC Recommendations

Recent picks made for AZN stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in AZN

Corporate Flights

Flights by private jets registered to AZN